PATENT CLAIM ANALYSIS

Application Number: 16051816
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2018-12
Patent Classification: ["514", "157000"]

Abstract:
The present disclosure provides compounds having Formula I-A: and the pharmaceutically acceptable salts and solvates thereof, wherein A, X 1 , X 2 , X 3  R 1a , R 1b , E, and   are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I-A for use to treat a disease, disorder, or condition responsive to Bcl-2 protein inhibition such as cancer.

Claim (Index 11):
The method of  claim 10 , wherein the cancer is selected from the group consisting of acute monocytic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, mixed lineage leukemia, NUT-midline carcinoma, multiple myeloma, small cell lung cancer, neuroblastoma, Burkitt's lymphoma, cervical cancer, esophageal cancer, ovarian cancer, colorectal cancer, prostate cancer, and breast cancer.

Metadata:
- Claim Count in Document: 18.0
- Percentile: 96.0
- Lexical Diversity: 1.48077
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['12641141', '14020761', '14625009', '12641063', '13929701']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.787224830115231
- 35 USC 102 Novelty (BERT): 0.5231278289266473
- Combined Prediction Score: 0.7608151299963727
- Mean Citation Score: 292.483582
- Max Citation Score: 300.64902
- Similarity Product: 201.00564462850568

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test